false 0001785173 0001785173 2024-05-29 2024-05-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 29, 2024

 

 

89bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39122   36-4946844

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

142 Sansome Street, Second Floor

San Francisco, CA 94104

(Address of principal executive offices, including zip code)

(415) 432-9270

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   ETNB   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

On Wednesday, May 29, 2024, 89bio, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) at 9:00 a.m. Pacific Time. As of the close of business on April 4, 2024, the record date for the Annual Meeting, there were 95,224,724 shares of common stock entitled to vote at the meeting.

At the Annual Meeting, each of the Company’s director nominees was elected, a frequency of one year received the plurality of votes on Proposal 4, and each of the other proposals voted on were approved. The final voting results are set forth below:

 

     Votes
For		      Votes
Withheld		      Broker
Non-Votes

Proposal 1. Election of Class II Directors

         

•   Steven M. Altschuler, M.D.

      78,767,873        870,306      5,519,919

•   Michael Hayden, M.B. Ch.B., Ph.D.

      74,810,576        4,827,603      5,519,919

•   Kathleen LaPorte

      41,297,162        38,341,017      5,519,919

 

     Votes
For		    Votes
Against		    Abstentions    Broker
Non-Votes

Proposal 2. Ratification of KPMG LLP as Independent Auditor

    85,047,829    21,903    88,366    0
     Votes
For		    Votes
Against		    Abstentions    Broker
Non-Votes

Proposal 3. Advisory Vote on Executive Compensation

    78,521,244    1,100,672    16,263    5,519,919

 

     1 Year    2 Years    3 Years    Abstentions    Broker
Non-Votes		  

Proposal 4. Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation

    68,467,710    4,205    17,657    11,148,607      5,519,919  

In light of these voting results, the Company plans to hold future advisory votes on executive compensation annually until the next required vote on the frequency of such advisory votes, or until the Board of Directors of the Company otherwise determines that a different frequency is in the best interests of the Company and its stockholders.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    89bio, Inc.
Date: May 31, 2024     By:  

/s/ Rohan Palekar

      Rohan Palekar
      Chief Executive Officer
v3.24.1.1.u2
Document and Entity Information
May 29, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001785173
Document Type 8-K
Document Period End Date May 29, 2024
Entity Registrant Name 89bio, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39122
Entity Tax Identification Number 36-4946844
Entity Address, Address Line One 142 Sansome Street
Entity Address, Address Line Two Second Floor
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94104
City Area Code (415)
Local Phone Number 432-9270
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol ETNB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Grafico Azioni 89bio (NASDAQ:ETNB)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di 89bio
Grafico Azioni 89bio (NASDAQ:ETNB)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di 89bio